Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSC intra-articular injection for knee osteoarthritis
IRCT20160704028786N3Phase 2Recruiting
- Sponsor
- Royan Institute
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Wharton's Jelly-derived Mesenchymal Stromal Cells and sodium hyaluronate in knee osteoarthritis (OA) (2 arms), sponsored by Royan Institute. Primary endpoints: Safety and Feasibility. Started Aug 2026; status: recruiting.
02
Drugs
Wharton's Jelly-derived Mesenchymal Stromal Cellssodium hyaluronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20160704028786N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160704028786N3.